MGuard meets primary endpoint in study of patients with CAD-InspireMD

InspireMD has announced new results from the iMOS Prime Registry demonstrating that use of the MGuard Prime in cases of acute ST-segment elevation myocardial infarction (STEMI) patients undergoing Percutaneous Coronary Intervention (PCI) resulted in complete ST-resolution in approximately 75% of cases, and a 2.2% rate of Major Adverse Cardiac Events (MACE) at 30 days, including zero cases of mortality. The iMOS Prime Registry evaluated the 'Real World' Clinical Performance of the MGuard Prime Coronary Stent System in patients with acute STEMI undergoing PCI.

Between December 13, 2012 and March 19, 2014, there were 97 patients with STEMI enrolled at two sites in the Netherlands. The iMOS Prime Registry achieved a 2.2% rate of Major Adverse Cardiac Events rate (MACE) at 30 days, the primary endpoint for the study. The MGuard Prime utilizes the Company's proprietary MicroNet technology, which is a circular knitted mesh that wraps around a cobalt chromium stent to protect patients from plaque debris flowing downstream upon deployment.